Researchers at Washington University engineered astrocytes expressing chimeric antigen receptors (CAR‑As) that reduced amyloid‑β plaque formation in Alzheimer’s mouse models after a single injection, reporting substantial plaque prevention and reduction in Science. The team positions CAR‑astrocytes as a potential cellular immunotherapy distinct from antibody dosing strategies. Complementary work from INSERM identified hypothalamic tanycytes as a previously unrecognized pathway for clearing tau protein; structural and genetic disruptions to tanycytes correlated with impaired tau clearance and may contribute to Alzheimer’s pathology. The findings were published in peer‑reviewed research from European collaborators. Together, these studies suggest two mechanistically different routes to reduce pathogenic protein burden—engineered glial immunotherapy and enhancement of endogenous clearance pathways—each with distinct translational challenges for safety and delivery.